Trastuzumab in combination with gemcitabine and vinorelbine as second-line therapy for HER-2/neu overexpressing metastatic breast cancer.
Oncol Rep
; 16(2): 393-8, 2006 Aug.
Article
em En
| MEDLINE
| ID: mdl-16820921
ABSTRACT
The aim of this study was to evaluate the safety and efficacy of combined treatment with trastuzumab (T), gemcitabine (gem) and vinorelbine (vin) as second-line therapy for HER-2 overexpressing metastatic breast cancer, pretreated with anthracyclines and/or taxanes and/or trastuzumab. Eligible patients had HER-2/neu-positive disease (IHC 2+ or 3+), performance status (PS)
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Vimblastina
/
Neoplasias da Mama
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Receptor ErbB-2
/
Desoxicitidina
/
Anticorpos Monoclonais
Limite:
Adult
/
Aged
/
Female
/
Humans
/
Middle aged
Idioma:
En
Ano de publicação:
2006
Tipo de documento:
Article